By The Life Science Report
Source: Streetwise Reports 03/19/2019
The biotech was selected to discuss its antibodies that selectively target toxic forms of alpha-synuclein.
ProMIS Neurosciences Inc. (PMN:TSX; ARFXF:OTCQB) announced in a news release it will present data in support of its new antibody candidates for Parkinson’s disease, at the 2019 Alzheimer’s & Parkinson’s Diseases Congress later this month.
Specifically at the conference, Dr. Neil Cashman, ProMIS’ chief scientific officer, will deliver the podium presentation, “Targeting of Pathogenic Aggregated Alpha-Synuclein: Refining Antibody Epitopes by Design,” on March 31. In it he will use ProMIS’ preclinical data to explain how the company developed antibodies that selectively bind to toxic forms of alpha-synuclein while sparing the healthy forms of it the body needs. The antibodies also block both, in vitro, the neurotoxicity and spread of the toxic forms of alpha-synuclein, which are considered a root cause of Parkinson’s.
On the prior day, March 30, Cashman will co-moderate the panel discussion, “Disease Mechanisms in Alzheimer’s and Parkinson’s Diseases.”
The AD/PD conference will take place March 26 to 31, 2019 in Lisbon, Portugal.
Free Reports:
Read what other experts are saying about:
Sign up for our FREE newsletter at: www.streetwisereports.com/get-news
Disclosure:
1) Doresa Banning compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. She or members of her household own securities of the following companies mentioned in the article: None. She or members of her household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: ProMIS Neurosciences. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports’ terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article until three business days after the publication of the interview or article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases. As of the date of this article, officers and/or employees of Streetwise Reports LLC (including members of their household) own securities of ProMIS Neurosciences, a company mentioned in this article.
( Companies Mentioned: PMN:TSX; ARFXF:OTCQB,
)